<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437463</url>
  </required_header>
  <id_info>
    <org_study_id>HOE498_6015</org_study_id>
    <nct_id>NCT00437463</nct_id>
  </id_info>
  <brief_title>Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor</brief_title>
  <official_title>Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA
      nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of proteinuria</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>body weight, blood pressure, pulse</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects of treatment</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>2.5mg and increase to 5mg if patient do not develop symptomatic hypotension</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-confirmed IgA nephropathy

          -  proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below
             120 Âµmol/l

        Exclusion Criteria:

          -  pregnant or nursing mother, or women of childbearing potential without an effective
             method of birth control

          -  history of myocardial infarction, congestive heart failure, or any other medical
             indication that necessitate the use of ACE inhibitor

          -  evidence of clinically significant hepatic, gastrointestinal, autoimmune disease

          -  history of malignancy, drug or alcohol abuse

          -  participation in any previous trial on ACE inhibitor

          -  taking other investigational drugs within the past 30 days

          -  known history of sensitivity / allergy to ACE inhibitor

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Yuen</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin A</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

